These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 12917817

  • 1. Targeted therapy in combination with gemcitabine in non-small cell lung cancer.
    Rosell R, Crino L, Danenberg K, Scagliotti G, Bepler G, Taron M, Alberola V, Provencio M, Camps C, De Marinis F, Sanchez JJ, Peñas R.
    Semin Oncol; 2003 Aug; 30(4 Suppl 10):19-25. PubMed ID: 12917817
    [Abstract] [Full Text] [Related]

  • 2. Influence of genetic markers on survival in non-small cell lung cancer.
    Rosell R, Taron M, Camps C, López-Vivanco G.
    Drugs Today (Barc); 2003 Oct; 39(10):775-86. PubMed ID: 14668933
    [Abstract] [Full Text] [Related]

  • 3. Genetic testing for chemotherapy in non-small cell lung cancer.
    Rosell R, Taron M, Alberola V, Massuti B, Felip E.
    Lung Cancer; 2003 Aug; 41 Suppl 1():S97-102. PubMed ID: 12867068
    [Abstract] [Full Text] [Related]

  • 4. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
    Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, Provencio M, Isla D, Taron M, Diz P, Artal A, Spanish Lung Cancer Group.
    Clin Cancer Res; 2004 Feb 15; 10(4):1318-25. PubMed ID: 14977831
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery.
    Rosell R, Felip E, Taron M, Majo J, Mendez P, Sanchez-Ronco M, Queralt C, Sanchez JJ, Maestre J.
    Clin Cancer Res; 2004 Jun 15; 10(12 Pt 2):4215s-4219s. PubMed ID: 15217961
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
    Mazzoni F, Cecere FL, Meoni G, Giuliani C, Boni L, Camerini A, Lucchesi S, Martella F, Amoroso D, Lucherini E, Torricelli F, Di Costanzo F.
    Lung Cancer; 2013 Nov 15; 82(2):288-93. PubMed ID: 24045016
    [Abstract] [Full Text] [Related]

  • 11. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.
    de las Peñas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, Massuti B, Queralt C, Botia M, Garcia-Gomez R, Isla D, Cobo M, Santarpia M, Cecere F, Mendez P, Sanchez JJ, Rosell R, Spanish Lung Cancer Group.
    Ann Oncol; 2006 Apr 15; 17(4):668-75. PubMed ID: 16407418
    [Abstract] [Full Text] [Related]

  • 12. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.
    Ceppi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV, Cambieri A, Selvaggi G, Saviozzi S, Calogero R, Papotti M, Scagliotti GV.
    Ann Oncol; 2006 Dec 15; 17(12):1818-25. PubMed ID: 16980606
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.
    Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, Lopez-Vivanco G, Camps C, Botia M, Nuñez L, Sanchez-Ronco M, Sanchez JJ, Lopez-Brea M, Barneto I, Paredes A, Medina B, Artal A, Lianes P.
    Ann Oncol; 2004 Aug 15; 15(8):1194-203. PubMed ID: 15277258
    [Abstract] [Full Text] [Related]

  • 17. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
    Zhang GB, Chen J, Wang LR, Li J, Li MW, Xu N, Wang Y, Shentu JZ.
    Cancer Chemother Pharmacol; 2012 May 15; 69(5):1277-87. PubMed ID: 22302408
    [Abstract] [Full Text] [Related]

  • 18. Pharmacogenomics and gemcitabine.
    Rosell R, Cobo M, Isla D, Camps C, Massuti B.
    Ann Oncol; 2006 May 15; 17 Suppl 5():v13-16. PubMed ID: 16807441
    [Abstract] [Full Text] [Related]

  • 19. Expression of ERCC1, RRM1 and LRP in non-small cell lung cancers and their influence on chemotherapeutic efficacy of gemcitabine concomitant with nedaplatin.
    Qiu ZQ, Zhao K.
    Asian Pac J Cancer Prev; 2014 May 15; 15(17):7303-7. PubMed ID: 25227833
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene.
    Kim SO, Jeong JY, Kim MR, Cho HJ, Ju JY, Kwon YS, Oh IJ, Kim KS, Kim YI, Lim SC, Kim YC.
    Clin Cancer Res; 2008 May 15; 14(10):3083-8. PubMed ID: 18483375
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.